Slides
Page 1
Q2 2026 EARNINGS PRESENTATION August 5 , 2026 Chemours ™
Page 2
Chemours - Internal Use Only This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the third quarter of 2026, the full year 2026 and the Company’s corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the U.S. or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and our Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law. We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this presentation, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position. Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP . This analysis, as well as the other information in this presentation, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this presentation may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com. Safe Harbor Statement and Other Matters 2
Page 3
Second Quarter 2026 Highlights Generated $1.6B in Net Sales and $247M in Adjusted EBITDA, supported by strong performance across all segments Repaid €230 million of the outstanding tranche of the B-3 Euro-denominated Term Loan due August 2028 in the quarter APM Performance Solutions net sales grew 8% YoY, underscoring momentum and mix shift towards high-value end markets for APM products Announced global TiO2 price increase effective June 1, 2026, as a continuation of December & April price actions; achieved a YTD TiO2 price increase of 5% Free Cash Flows improved 128% YoY, with conversion of 46% and net leverage declining to 4.4x, advancing toward a long-term target of below 3x 3
Page 4
Chemours - Internal Use Only Second Quarter 2026 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) 2Q26 2Q25 Y-o-Y ∆ 1Q26 Q-o-Q ∆ Net Sales $1,591 $1,615 ($24) $1,381 $210 Net (Loss) / Income1 ($274) ($380) $106 ($29) ($245) Adj. Net Income 2 $64 $91 ($27) $8 $56 EPS 3 ($1.81) ($2.53) $0.72 ($0.19) ($1.62) Adj. EPS 2,3 $0.42 $0.61 ($0.56) $0.05 $0.36 Adj. EBITDA 2,4 $247 $260 ($13) $169 $78 Operating Cash Flow $158 $93 $65 ($44) $202 Capex ($44) ($43) $1 ($49) $5 Free Cash Flow $114 $50 $64 ($93) $207 FCF Conversion 46% 19% 27% (55)% 101% 4 1 Net (Loss) / Income attributable to The Chemours Company. 2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items. Please refer to the attached "GAAP Net (Loss) IncomeAttributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)” table. 3 Calculation based on diluted share count. 4 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached “GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)” table. .
Page 5
Chemours - Internal Use Only Adjusted EBITDA Bridge: 2Q26 versus 2Q25 $260 $247 $35 ($33) $8($23) 2Q25 Price Volume Cost/Other Currency 2Q26 ($ in millions) Price Impacts: $35 million due to higher pricing across the three primary segments, with strength in TiO2 pricing tied to the three disclosed pricing actions since December of 2025. Volume Impacts: ($33) million due to lower stationary AC aftermarket refrigerant sales of TSS Opteon blends in North America, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act, as well as lower volumes associated with the APM SPS Capstone line closure completed in the third quarter of 2025 Cost/Other: ($23) million primarily driven by inflationary pressures experienced across the portfolio, partially offset by global net cost reduction efforts. Currency: $8 million primarily driven by favorable currency dynamics within the TT and TSS business units. See reconciliation of Non-GAAP measures in the Appendix 5
Page 6
Chemours - Internal Use Only APM $345 $346 $326 2Q24 2Q25 2Q26 $160 $207 $213 2Q24 2Q25 2Q26 Quarterly Segment Summary ($ in millions unless otherwise noted) 31% 35% 36% Net Sales Adjusted EBITDA and Margin (%) $519 $596 $591 2Q24 2Q25 2Q26 TSS TSS 12% 7% 7% 13% 14% 8% TT $677 $657 $661 2Q24 2Q25 2Q26 TT $83 $47 $48 2Q24 2Q25 2Q26 APM $45 $50 $26 2Q24 2Q25 2Q26 6
Page 7
Chemours - Internal Use Only $562 Unrestricted $671 Unrestricted $53 Restricted $158 ($44) ($13) $7 $52 Restricted 1Q26 Cash Balance Operating Cash Flows Capex Cash to Shareholders Other 2Q26 Cash Balance Liquidity Position as of June 30, 2026 ($ in millions unless otherwise noted) 5 $3.9B $3.2B 4.4x Gross Debt TTM Net Leverage 9 Net Debt 8 $1.6BTotal Liquidity 7 56 5 Total cash balances include $52 million and $53 million of restricted cash and restricted cash equivalents on Chemours’ Balance Sheets as of June 30, 2026 and December 31, 2025, respectively. Restricted cash of $53 million at the end of thefirst quarter and $52 million at the end of the second quarter includes cash and cash equivalents held in escrow under the terms of the Memorandum of Understanding (MOU) related to potential future legacy liabilities. 6 Cash to shareholders reflects approximately $15 million in dividends paid to shareholders during the second quarter of 2026. 7 Total liquidity is calculated as the sum of $671 million unrestricted cash and cash equivalents and $953 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents totaling $52 million is not included in this calculation. The Company announced an amendment and extension to its credit agreement in May 2025. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion until October 2026, comprised of $780 million maturing on May 2, 2030, and $220 million on October 7, 2026. 8 Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents. 9 TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA. 7 $615 $723
Page 8
STRA TEGIC PROGRESS P A THWA Y TO THRIVE
Page 9
PATHWAY TO THRIVE Balanced & Disciplined Capital Allocation To Create Shareholder Value Expanding Free Cash Flow Conversion & Long-Term Objective of Net Leverage Below 3x Across Economic Cycles Operational Excellence ❑Manufacturing excellence as a basis for success ❑Improved and standardized operating model for consistent execution ❑Continuous improvement to adapt to changing markets Strengthening the Long-Term ❑Measurable progress on resolving legacy liabilities in the interest of stakeholders ❑Responsible manufacturing practices ❑Targeted policy efforts Enabling Growth ❑Investing smartly in selected growth projects ❑Commercial effectiveness to drive sales growth ❑Innovation and new product development Portfolio Management ❑Holistic portfolio analysis focused on distinct value creation metrics ❑Shift product mix to higher value applications in growing end markets ❑Optimize asset footprint >$250M cost reduction from 2024 to 2027 Recognizing criticality of our chemistriesDriving shareholder value >5% Sales CAGR from 2024 to 2027 9 Our Strategy
Page 10
Chemours - Internal Use Only Progress Achieved to Date PATHWAY TO THRIVE Balanced & Disciplined Capital Allocation: Received ~$287M initial net proceeds from the sale of the Kuan Yin site, positioning the Company to paydown €230M of outstanding debt, and helping to progress towards the long-term goal of below 3x net leverage Operational Excellence ✓ Notable progress against the $250M of run-rate savings by end of 2027 across all areas of the company ✓ Advanced the Chemours Business System rollout, embedding Lean principles to drive continuous improvement in safety, quality, and reliability ✓ Executed a long-term chlorine supply agreement with Olin Corporation, supporting the long-term competitiveness of the DeLisle TiO2 site Strengthening the Long-Term ✓ Reached a settlement with the EPA & WVDEP to resolve alleged permitting violations across three Chemours sites ✓ Agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all environmental claims, including PFAS statewide ✓ Addressed nearly $2B of near-term debt maturities in the past 6 months ✓ Drove advocacy for the importance of Chemours’ essential chemistry as a part of recent U.S. trade policy changes and evolving EU regulatory landscape Enabling Growth ✓ Recorded initial sales of less than $1 million for two-phase fluids during 2Q26 ✓ Continued sales in high-growth semiconductor and data center end markets contributing more than 40% of APM Performance Solutions sales ✓ Successful qualification of Chemours’ two-phase immersion cooling fluid by Samsung Electronics and 2CRSi ✓ Implemented three global TiO2 pricing increases in the past 8 months, reflecting Chemours’ value in reliability and quality Portfolio Management ✓ Progressed APM European asset review, through the announced exit of the Villers-St. Paul site ✓ Exited SPS Capstone business to prioritize higher return businesses and strengthen Chemours’ overall portfolio ✓ Closed a substantial tranche of the announced sale of the former Kuan Yin TiO2 site in April 2026 ✓ Shifted aspects of TT’s mining operations to prioritize cash flow generation 10
Page 11
Established Participation Focused on AI Infrastructure Semiconductor Fabrication Use Cases Data Center Use Cases Thermal Management ➢ Opteon and Freon refrigerants support current cooling infrastructure ➢ Insulation and coatings for temperature and humidity control Specialty Fluid Transfer ➢ Teflon coatings for wafer etching fluid handling ➢ Teflon coatings for gas and liquid filtration Performance Materials ➢ Teflon coatings for cable insulation, in-tool components, tank lining, and AF optical networking ➢ Krytox greases and oils for vacuum pumps and robotic systems ➢ Viton fluoroelastomers for component sealing TSS’ Opteon and Freon refrigerants serve today’s data center installed base, while developing two-phase liquid cooling solutions support the next generation of data center infrastructure APM Performance Solutions’ Teflon , Krytox , and Viton satisfy critical needs in data centers and semiconductor fabs to extend service life, improve chip yields, and increase reliability TSS / APM approximate a high-single-digit sales concentration in data center, semiconductor and advanced electronics, anticipated to experience robust growth in years ahead. More than 40% of APM’s Performance Solutions sales are concentrated in these targeted markets.
Page 12
12 Expanding Applications & R&D Priorities for AI Infrastructure Two-Phase Immersion Cooling Two-Phase Direct to Chip 1 3 2 4 Liquid thermal management fluids circulate into the server rack manifold through a closed loop system The fluid boils, exiting the cold plate as a vapor The manifold is connected to a specialized cold plate located directly on top of the chip which is used to cool down the chip, transferring heat to the fluid in the process The vapor returns to a Coolant Distribution Unit (CDU) to be condensed back to a liquid and recirculated back to the cold plate, repeating the closed loop Electronic equipment is submerged in Opteon 2P50 in a sealed container, allowing the fluid to directly contact the entire ecosystem, not just the chip 1 The heat from the electronic equipment causes the fluid to boil 2 3 Vapor rises and condenses back to a liquid when it makes contact with the condenser coil 4 The fluid returns to the pool in a passive cycle Annual R&D investment of ~$20-25M focused on: ➢ Next-generation refrigerants to address evolving customer & regulatory needs ➢ Two-phase cooling technologies to enable next-generation chips, optimize total cost of ownership, and support AI scaling 1 2 3 4 Two-Phase Immersion Cooling Differentiators ✓ Near zero water usage with closed loop immersion design ✓ 100% heat capture by cooling all IT components simultaneously ✓ Exceptional energy efficiency with zero fan and minimal mechanical cooling requirements ✓ Extended lifetime of the IT hardware equipment thanks to homogenous temperature Two-Phase Direct to Chip Differentiators ✓ High thermal performance via direct phase change cooling ✓ Near zero water usage with closed loop direct-to-chip design ✓ Preserves standard server architecture by cooling high heat components directly ✓ Easy retrofits into existing data centers 1 2 3 4 Liquid Cooling & NGR additional areas of investment to continue to drive growth in data center cooling for years ahead.
Page 13
Third Quarter GUIDANCE
Page 14
Third Quarter and Full Year 2026 Guidance Sequential Business Outlook: Consolidated o Net Sales: Expected to decrease in the (5%) to 0% range sequentially o Adjusted EBITDA: Expected to range between $175 million and $205 million o Corporate Expenses: Expected to range between $40 million and $45 million o Capital Expenditures: Expected to approximate $65 million o Free Cash Flow Conversion: Reflecting a source of cash of at least $50 million TSS o Net Sales: Expected to decrease in the mid-teens to twenty percentage range, driven by less favorable seasonality in connection with the 2026 cooling season in the Northern Hemisphere and weaker Opteon blends aftermarket refrigerant demand in North America elevated market inventory levels from the initial channel fill in mid-2025 o Adjusted EBITDA: Expected to approximate $125 million to $140 million, primarily driven by the referenced less favorable seasonality. TT o Net Sales: Expected to increase in the low-to-mid single digits percentage range, driven by recent pricing announcements, with stable volumes o Adjusted EBITDA: Expected to range between $70 million and $80 million, driven by the referenced recent pricing actions. APM o Net Sales: Expected to increase in the mid-to-high single digits percentage range, driven by a return to normal operating levels at the Washington Works facility and continued strength in the Performance Solutions order book. o Adjusted EBITDA: Expected to be between $20 million and $30 million, driven by the referenced return to normal operations within APM’s operational circuit and order book strength. CapEx $250M - $280M Adjusted EBITDA $775M - $825M Net Sales Growth 1 – 5% Full Year 2026 Outlook Free Cash Flow Conversion 25%+ Third Quarter 2026 Outlook 14
Page 15
APPENDIX 15
Page 16
Chemours - Internal Use Only OpteonTM Refrigerants 63% OpteonTM Refrigerants 57% FreonTM Refrig. 21% $20 $(26) FreonTM Refrigerants 25% FP&O 17% FP&O 18% 2Q25 Price/Currency Volume 2Q26 16 TSS Segment Net Sales and Adjusted EBITDA (Unaudited) $207 $213 2Q25 Price/Currency Volume Cost/Other 2Q26 ($ in millions) % of total Net Sales ($ in millions) Net Sales: The 1% year-over-year decrease was driven lower stationary AC aftermarket refrigerant sales of TSS Opteon blends in North America, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act, partially offset by higher Freon prices, primarily in automotive applications. Adjusted EBITDA: The increase reflects the referenced pricing activity, aided by the timing of certain costs, in the quarter. 2Q26 % total refrigerants: Freon = 31% Opteon = 69% 2Q25 % total refrigerants: Freon = 25% Opteon = 75% $597 $591
Page 17
Chemours - Internal Use Only TiO2 96% TiO2 97% Minerals 4% $19 $(15) Minerals 3% 2Q25 Price/Currency Volume 2Q26 17 TT Segment Net Sales and Adjusted EBITDA (Unaudited) $47 $48 2Q25 Price/Currency Volume Cost/Other 2Q26 ($ in millions) Net Sales: The increase was driven by a 2% increase in global pricing and a 1% currency tailwind, more than offsetting a 2% decline in global volumes. Pricing increased across all regions, while the volume decline was driven by lower TiO2 sales across key end markets, with the exception of Asia excluding China and Latin America. Adjusted EBITDA: The increase in Adjusted EBITDA was primarily driven by the referenced global pricing strength, partially offset by higher costs due to inflation. ($ in millions) $657 $661
Page 18
Chemours - Internal Use Only $50 $26 2Q25 Price/Currency Volume Cost/Other 2Q26 Advanced Materials 62% Advanced Materials 56% Performance Solutions 38% $11 ($32) Performance Solutions 44% 2Q25 Price/Currency Volume 2Q26 18 APM Segment Net Sales and Adjusted EBITDA (Unaudited) Net Sales: The 6% decrease was primarily driven by a 9% decrease in volumes, partially offset by a 2% increase in price and a slight currency tailwind. The volume decline was primarily driven by the APM SPS Capstone line closure completed in the third quarter of 2025. Performance Solutions Net Sales increased 8% year-over-year, supported by order book strength and continued momentum in high-value specialty products serving data center and semiconductor end markets Adjusted EBITDA: The decrease in Adjusted EBITDA was primarily driven by lower volumes due to the referenced product line exit and operational impacts related to the previously disclosed and resolved outage at the Washington Works site. ($ in millions) % of total Net Sales ($ in millions) $346 $326
Page 19
Chemours - Internal Use Only 19 Segment Net Sales (Unaudited) 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Net sales by product group and segment OpteonTM refrigerants 200$ 227$ 205$ 178$ 279$ 375$ 368$ 243$ 313$ 337$ Freon TM refrigerants 173 173 146 124 97 123 98 113 162 150 Foam, propellants, and other 81 119 117 88 90 99 94 88 93 104 Total Thermal & Specialized Solutions 454 519 468 390 466 597 560 444 568 591 Titanium Dioxide 562 643 642 598 575 629 591 534 541 639 Minerals & Other 30 33 30 34 22 28 21 27 18 22 Total Titanium Technologies 592 676 672 632 597 657 612 561 559 661 Advanced materials 190 212 214 191 178 214 190 172 143 184 Performance solutions 113 133 140 133 116 132 121 141 100 142 Total Advanced Performance Materials 303 345 354 324 294 346 311 312 243 326 Performance chemicals and intermediates 14 13 14 13 11 15 12 12 11 13 Total Other Segment 14 13 14 13 11 15 12 12 11 13 Total net sales 1,363$ 1,553$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ 1,329$ 1,381$ 1,591$ 2024
Page 20
Chemours - Internal Use Only 20 Segment Net Sales by Region (Unaudited) 1 LATAM includes Mexico. 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Net sales by geographic region North America: Thermal & Specialized Solutions 271$ 308$ 256$ 194$ 233$ 336$ 316$ 241$ 326$ 340$ Titanium Technologies 246 274 270 236 267 282 252 221 235 267 Advanced Performance Materials 124 133 130 112 111 125 110 131 95 140 Other Segment 9 10 9 7 8 10 7 7 7 7 Total North America 650 725 665 549 619 753 685 599 663 754 Asia Pacific: Thermal & Specialized Solutions 39 53 55 53 53 59 69 53 71 72 Titanium Technologies 147 178 171 161 105 125 122 114 77 124 Advanced Performance Materials 105 127 138 148 115 147 138 132 89 117 Other Segment 3 2 3 3 2 3 3 3 2 4 Total Asia Pacific 294 360 367 365 275 334 332 301 239 317 Europe, the Middle East, and Africa: Thermal & Specialized Solutions 92 103 98 69 98 112 87 84 97 97 Titanium Technologies 124 130 126 131 142 156 141 128 151 156 Advanced Performance Materials 63 72 70 53 56 60 52 40 52 57 Other Segment 2 1 2 2 1 2 2 2 2 2 Total Europe, the Middle East, and Africa 281 306 296 255 297 330 282 254 302 312 Latin America (1): Thermal & Specialized Solutions 52 55 59 74 82 90 88 66 74 82 Titanium Technologies 74 95 105 104 83 94 97 99 96 114 Advanced Performance Materials 11 13 16 11 12 14 11 10 7 12 Other Segment — — — 1 — — — — — — Total Latin America 137 163 180 190 177 198 196 175 177 208 Total net sales 1,362$ 1,554$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ 1,329$ 1,381$ 1,591$ 2024
Page 21
Chemours - Internal Use Only 21 Segment Net Sales and Adjusted EBITDA (Unaudited) 2025 2026 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Segment Net Sales Thermal & Specialized Solutions 454$ 519$ 468$ 390$ 466$ 597$ 560$ 444$ 568$ 591$ Titanium Technologies 592 676 672 632 597 657 612 561 559 661 Advanced Performance Materials 303 345 354 324 294 346 311 312 243 326 Other Non-Reportable Segment 14 13 14 13 11 15 12 12 11 13 Total Company Net Sales 1,363$ 1,553$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ 1,329$ 1,381$ 1,591$ Segment Adjusted EBITDA Thermal & Specialized Solutions 150$ 160$ 139$ 122$ 141$ 207$ 194$ 128$ 190$ 213$ Titanium Technologies 69 83 78 70 50 47 25 23 18 48 Advanced Performance Materials 30 45 38 47 32 50 14 12 5 26 Other Non-Reportable Segment 2 3 3 - 1 4 2 1 3 2 Corporate Expenses (55) (77) (54) (69) (57) (47) (44) (34) (47) (42) Segment Adjusted EBITDA Margin Thermal & Specialized Solutions 33% 31% 30% 31% 30% 35% 35% 29% 33% 36% Titanium Technologies 12% 12% 12% 11% 8% 7% 4% 4% 3% 7% Advanced Performance Materials 10% 13% 11% 15% 11% 14% 5% 4% 2% 8% Other Non-Reportable Segment 14% 23% 21% 0% 9% 27% 17% 10% 27% 15% 2024
Page 22
Chemours - Internal Use Only 22 GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 1/2) ($ in millions except per share amounts) $ amounts $ per share* $ amounts $ per share* $ amounts $ per share* $ amounts $ amounts (Loss) income before income taxes (1)$ (248)$ (22)$ (52)$ (292)$ Net (loss) income attributable to Chemours (274)$ (1.79)$ (380)$ (2.52)$ (29)$ (0.19)$ (303)$ (428)$ Non-operating pension and other post-retirement benefit income (3) (0.02) (2) (0.01) (2) (0.01) (12) (5) Exchange losses (gains), net 1 0.01 4 0.03 (1) (0.01) 5 10 Restructuring, asset-related, and other charges 3 0.02 18 0.12 13 0.09 24 100 Goodwill impairment charge — — — — — — — 56 Loss on extinguishment of debt 2 0.01 — — 9 0.06 16 1 Gain on sales of assets and businesses, net (266) (1.74) — — — — (273) (1) Transaction costs — — 2 0.01 2 0.01 6 4 Qualified spend recovery (6) (0.04) (13) (0.09) (5) (0.03) (31) (33) Litigation-related charges 225 1 293 1.95 20 0.13 272 296 Environmental charges 144 0.94 60 0.40 7 0.05 184 75 Adjustments made to income taxes 207 1 179 1.19 1 0.01 209 191 Provision for (benefit from) income taxes relating to reconciling items 31 0 (70) (0.47) (7) (0.05) 8 (81) Adjusted Net Income 64$ 0.42$ 91$ 0.61$ 8$ 0.05$ 105$ 185$ Net income attributable to non-controlling interests — 1 — (1) 1 Interest expense, net 68 67 69 273 268 Depreciation and amortization (11) 80 79 79 320 304 All remaining provision for income taxes 35 22 13 36 37 Adjusted EBITDA 247$ 260$ 169$ 733$ 795$ June 30, March 31, June 30, Three Months Ended Three Months Ended Twelve Months Ended 2026 2025 2025 2026 2025
Page 23
Chemours - Internal Use Only 23 GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 2/2) ($ in millions except per share amounts) $ amounts $ per share* $ amounts $ per share* $ amounts $ per share* $ amounts $ amounts Adjusted EBITDA 247$ 260$ 169$ 733$ 795$ Total debt principal 3,914$ 4,183$ Less: Cash and cash equivalents (671) (502) Total debt principal, net 3,243$ 3,681$ Net Leverage Ratio (calculated using GAAP earnings) -62.4x (12.6)x Net Leverage Ratio (calculated using Non-GAAP earnings) 4.4x 4.6x Weighted-average number of common shares outstanding - basic 151,225,044 150,238,691 150,767,077 Weighted-average number of common shares outstanding - diluted 152,813,557 150,506,761 151,586,805 Basic (loss) earnings per share of common stock (2) (1.81)$ (2.53)$ (0.19)$ Diluted (loss) earnings per share of common stock (1) (2) (1.81)$ (2.53)$ (0.19)$ Adjusted basic earnings per share of common stock (2) 0.42$ 0.61$ 0.05$ Adjusted diluted earnings per share of common stock (1) (2) 0.42$ 0.61$ 0.05$ June 30, March 31, June 30, Three Months Ended Three Months Ended Twelve Months Ended 2025 (1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended March 31, 2025 and December 31, 2024. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended March 31, 2025 and December 31, 2024 as Adjusted Net Income was in a net income position. (2) Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers. 2026 2025 2025 2026
Page 24
Chemours - Internal Use Only 24 GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation Cash flows (used for) provided by operating activities $ 158 $ 93 $ (44) $ 114 $ (19) Less: Purchases of property, plant, and equipment (44) (43) (49) (93) (127) Free Cash Flows $ 114 $ 50 $ (93) $ 21 $ (146) Adjusted EBITDA 247 260 169 416 426 Free Cash Flow Conversion 46% 19% (55)% 5% (34)% 2026 2025 2026 2026 2025 Three Months Ended Six Months Ended June 30, March 31, June 30,
Page 25
Chemours - Internal Use Only 25 2026 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation; 2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation
Page 26
® 2026 CHEMOURS. ALL RIGHTS RESERVED